Blinded RCT, 268 adults with moderate-to-severe major depressive disorder in Italy: pharmacogenetic-guided treatment vs treatment as usual did not significantly improve response or remission at weeks 8 and 12. Subgroup with severe symptoms had higher week-8 response.
RCTn = 268
Minelli et al. Does pharmacogenetic testing optimize antidepressant effectiveness in major depressive disorder? Data from a double-blind randomized controlled trial in a real-world clinical setting